Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity

Lourdes Roque-Navarro, Krittalak Chakrabandhu, Joel De León, Sandra Rodríguez, Carlos Toledo, Adriana Carr, Cristina Mateo De Acosta, Anne Odile Hueber, Rolando Pérez

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

58 Citas (Scopus)


Gangliosides have been involved in multiple cellular processes such as growth, differentiation and adhesion, and more recently as regulators of cell death signaling pathways. Some of these molecules can be considered as tumor-associated antigens, in particular, N-glycolyl sialic acid-containing gangliosides, which are promising candidates for cancer-targeted therapy because of their low expression in normal human tissues. In this study, we provided the molecular and cellular characterization of a novel cell death mechanism induced by the anti-NGcGM3 14F7 monoclonal antibody (mAb) in L1210 murine tumor cell line but not in mouse normal cells (B and CD4+ T lymphocytes) that expressed the antigen. Impairment of ganglioside synthesis in tumor cells abrogated the 14F7 mAb cytotoxic effect; however, exogenous reincorporation of the ganglioside did not restore tumor cell sensitivity to 14F7 mAb-induced cytotoxicity. 14F7 F(ab′)2 but not Fab fragments retained the cytotoxic capacity of the whole mAb. By contrary, other mAb, which recognizes N-glycolylated gangliosides, did not show any cytotoxic effect. These mAbs showed quite different capacities to bind NGcGM3-positive cell lines measured by binding inhibition experiments. Interestingly, this complement-independent cell death mechanism did not resemble apoptosis, because no DNA fragmentation, caspase activation, or Fas mediation were observed. However, NGcGM3 ganglioside-mediated 14F7 mAb-induced cell death was accompanied by cellular swelling, membrane lesion formation, and cytoskeleton activation, suggesting an oncosislike phenomenon. This novel mechanism of cell death lets us to support further therapeutic approaches using NGcGM3as a molecular target for antibody-based cancer immunotherapy.

Idioma originalInglés
Páginas (desde-hasta)2033-2041
Número de páginas9
PublicaciónMolecular Cancer Therapeutics
EstadoPublicada - 2008
Publicado de forma externa


Profundice en los temas de investigación de 'Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity'. En conjunto forman una huella única.

Citar esto